Compare GDV & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDV | MLYS |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | N/A | 2023 |
| Metric | GDV | MLYS |
|---|---|---|
| Price | $29.22 | $28.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $48.67 |
| AVG Volume (30 Days) | 92.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.10 | $12.59 |
| 52 Week High | $29.46 | $47.65 |
| Indicator | GDV | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 52.12 |
| Support Level | $26.24 | $26.85 |
| Resistance Level | $29.46 | $31.19 |
| Average True Range (ATR) | 0.37 | 1.71 |
| MACD | 0.16 | 0.18 |
| Stochastic Oscillator | 92.54 | 40.56 |
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, including Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services, and others.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.